The American Hospital Association is blasting a court ruling siding with the Pharmaceutical Research and Manufacturers of America over the 340B Orphan Drug program, according to AHA Executive Vice President Tom Nickels.
"The ruling excludes all drugs with an 'orphan' designation from the 340B Drug Pricing Program for rural and cancer hospitals," Nickels said in a statement. "Denying these hospitals the ability to utilize 340B discounts for these drugs will reduce access to critical services and treatments for some of the most vulnerable patients in society."
Read Full Article »